Allison Kutner

Cooley advised Poseida Therapeutics, a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated nonviral treatments for patients with cancer, autoimmune and rare diseases, on its merger agreement to be acquired by Roche at a price of $9 per share in cash at closing, plus a non-tradable contingent value right to receive up to an aggregate of $4 per share in cash, payable upon achievement of specified milestones. The price payable at closing represents a total equity value of up to $1.5 billion and a premium of approximately 215% to Poseida’s closing share price on November 25, 2024. Cooley previously represented Poseida in its initial public offering, equity and debt transactions, and collaboration agreements, including its collaboration agreement with Roche.

Cooley advised the underwriters of Septerna, a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, on its upsized $331.2 million initial public offering.

Cooley advised RTZ Systems, an information technology and services company, on its acquisition by CollabriOS Health, a new entity formed by Assured Healthcare Partners that brings together a suite of integrated technology infrastructure, including electronic health records, third-party administrator financial services, and care coordination solutions designed to help Programs of All-Inclusive Care for the Elderly (PACE) optimize workflows, streamline business processes and enhance overall center operations.

Cooley advised Expert Institute (EI), a provider of outsourced legal services to the attorney market, on its acquisition by Levine Leichtman Capital Partners, a Los Angeles-based private equity firm, from Spectrum Equity, a growth equity firm that provides capital and strategic support to innovative companies in the information economy, in partnership with management.

Cooley advised Morgan Stanley, Jefferies, Citigroup and Guggenheim Securities as the underwriters of Zenas BioPharma’s $225 million initial public offering.